FASENRA- benralizumab injection, solution

AstraZeneca Pharmaceuticals LP

FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. (1)

Limitations of Use:
• Not for treatment of other eosinophilic conditions. (1)
• Not for relief of acute bronchospasm or status asthmaticus. (1)

Store refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light.

If needed, the prefilled syringe and autoinjector may be stored at room temperature up to 77°F (25°C) for a maximum of 14 days in the original carton to protect from light. Once removed from the refrigerator and brought to room temperature (up to 77°F [25°C]), the prefilled syringe and autoinjector must be used within 14 days or discarded.

Do not freeze. Do not shake. Do not expose to heat.